MRVI
Maravai Lifesciences Holdings, Inc.
A maker of the raw ingredients behind mRNA vaccines and therapies, Maravai LifeSciences supplies everything from its CleanCap® capping technology to impurity-detection kits used by biopharma and diagnostics companies in roughly sixty countries through its TriLink and Cygnus brands. Formed in 2014 by Carl Hull, Eric Tardif, and the private-equity firm GTCR, it grew by buying scientifically driven companies like TriLink and Cygnus. Its CleanCap® technology was a key ingredient in the Pfizer-BioNTech COVID-19 vaccine, and its name is the northern Italian word for "miracle."
CUSIP: 56600D107HealthcareUS2 holders
Total Value
$9.65M
Total Shares
3.41M
Net Share Change
+725.0K
Activity
1 buying
Investor
Value
Shares
Weight
Change
